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Abstract
On September 12, 2013, Eli Lilly & Co., in filing its Notice of Arbitration with the North
American Free Trade Agreement against the Government of Canada, became the first private
investor to contest a national patent regime through arbitral means. In the Notice, Lilly alleges
that Canada violated NAFTA Articles 1110 (covering expropriation) and 1105 (covering mini-
mum standards of treatment) by allowing Canada Federal Courts to unlawfully invalidate two of
Lilly's patents, CA 2,041,113 and CA 2,209,735, protecting the compounds comprising Zyprexa
and Strattera, respectively, through application of its controversial "promise doctrine." Whether
arbitration through NAFTA is an appropriate way to contest a NAFTA member state's patent
regime is hotly contested. But Canada Federal Courts have invalidated an increasing number of
pharmaceutical patents for failing to meet the promise doctrine, leaving pharmaceutical companies
in Canada uncertain as to the extent of their patent rights. Still, NAFTA allowing pharmaceuti-
cal companies to successfully dispute national patent laws could have significant future consequences.
This note outlines the circumstances surrounding Lilly's dispute, analyzes the dispute's viability,
and explores various potential implications of the dispute going forward.
I. Introduction
On September 12, 2013, Eli Lilly & Company (Lilly) shocked the legal world when it
filed a "Notice of Arbitration" (Notice) under Chapter 11 of the North American Free
Trade Agreement (NAFTA) against the Government of Canada (Canada) for permitting
its courts to apply certain patent restrictions in particular ways.' For the first time ever, a
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1. See generally Eli Lilly & Co. v. Canada, Notice of Arbitration, In the Arbitration under the Arbitration
Rules of the United Nations Commission on International Trade Law and the North American Free Trade
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trade agreement is being used as a means to challenge aspects of a national patent regime. 2
In the arbitration notice, Lilly seeks CND $500 million in damages from Canada for
allowing its courts to misapply the "doctrine of sound prediction" (also known as the
"promise doctrine").3 Lilly filed the arbitration notice in response to the Canada Federal
Court of Appeal (the Court of Appeal) retroactively invalidating two patents, CA
2,041,113 (the '113 patent) and CA 2,209,735 (the '735 patent) (collectively, the Lilly
patents), which safeguarded Lilly's privilege in Canada to the compounds comprising
Zyprexa and Strattera, respectively.4
Whether arbitration under NAFTA is an appropriate way to contest a member state's
(Party's) patent regime is a hotly contested issue.5 But Canada has a growing number of
pharmaceutical patents being invalidated for failing to meet the promise doctrine, 6 leaving
pharmaceutical companies uncertain as to the scope of their patent rights.7 Accordingly,
recourse should arguably be available for pharmaceutical companies under similar circum-
stances.8 Yet, allowing pharmaceutical companies to seek remedy under NAFTA from
national patent laws could have significant implications going forward.9
This note will outline the circumstances surrounding Lilly's decision to pursue Chapter
11 arbitration and analyze the dispute's viability. Additionally, this note will explore po-
tential future consequences of Lilly's arbitration filing. Part II of this note will explain the
law and facts leading up to, and surrounding, Lilly's arbitration notice. Part III will ana-
lyze whether Lilly's Chapter 11 claims, specifically under Articles 1110 and 1105, are
legally viable and will conclude that they likely are. Lastly, Part IV will discuss potential
implications of Lilly's challenge going forward, even in the absence of a favorable verdict
for Lilly.
Agreement (Sept. 12, 2013) available at http://www.international.gc.ca/trade-agreements-accords-com-
merciaux/assets/pdfs/disp-diff/eli-03.pdf [hereinafter Notice of Arbitration].
2. See Latha Jishnu, A Treaty Too Many, DowN To EARTH, May 15, 2013, available at http://www.down-
toearth.org.in/content/treaty-too-many ("Eli Lilly . . . issued a notice of intent to challenge Canada's patent
policy under ... NAFTA. Such arbitration is likely to open a Pandora's box. So far patent policies have not
come under the investor-state mechanism . . . .").
3. See Notice of Arbitration, supra note 1, 919172, 85(i).
4. See id. 21; see also Eli Lilly Can. Inc. v. Novopharm Ltd., [20121 F.C.A. 232 (Can.); see also Eli Lilly &
Co. v. Teva Can. Ltd., [2011] F.C.A. 220 (Can.).
5. See, e.g., Eli Lilly Files jor NAFTA Arbitration in $500M Drug Patent Dispute with Ottawa, CAN. PREsS
(Sept. 13, 2013, 4:53 PM), available at http://www.ctvnews.ca/business/eli-lilly-files-for-nafta-arbitration-in-
500m-drug-patent-dispute-with-ottawa-1.1454069 ("The [Lilly] challenge comes amid ongoing debate re-
garding investor protection rights in Canada's trade agreements . . . .").
6. See, e.g., Notice of Arbitration, supra note 1, 1 11 ("Since the advent of the promise doctrine, 18 phar-
maceutical patents have been invalidated for lack of utility in Canada. In the prior 25 years, only two patents
were invalidated for lack of utility . . . .").
7. See id. 1 11, 12 ("[E]very patent invalidated since 2005 for lack of utility has been a pharmaceutical
invention. Canada's adoption of the promise doctrine was a watershed event in the development of Canada's
intellectual property regime.").
8. See id. 1 12 ("Not only is Canada applying a utility test that violates the standard required under
NAFTA, it is also applying the utility test in a way that discriminates against pharmaceuticals as a field of
technology. This itself contravenes Canada's obligation under NAFTA Article 1709(7) to make patents avail-
able and patent rights enjoyable without discrimination.").
9. See Jishnu, supra note 2.
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II. Background
Lilly, founded by a Civil War veteran in 1876,1o has grown into the tenth-largest phar-
maceutical company in the world." It is a leader in research and development for psychi-
atric and mental-health medicines,12 having brought to market some of the highest
grossing drugs of all time.13 Although its greatest presence is in the United States,' 4 Lilly
develops, manufactures, markets, and sells medicines across the globe.15 Like other major
pharmaceutical conglomerates, Lilly faces significant economic burdens from various
sources, like pro-generic legislationl6 and industry-wide regulation.' 7 Even product de-
velopment costs stagger; every new drug brought to market sets companies back an aver-
age of USD $5 billion.'8 In a country without sufficiently "protective" laws, drug
developers like Lilly would have no choice but to avoid the risks of innovation and slow or
halt development altogether. So, Lilly depends on intellectual property rights-the "life-
blood . . . for innovation"' 9-to generate "sufficient financial incentives to pursue R&D"
of enhanced medicines. 20
Zyprexa and Strattera, used for schizophrenia treatment and attention-deficit hyperac-
tivity disorder (ADHD), respectively, are two of Lilly's medicines that it would likely de-
scribe as "enhanced." 21 Zyprexa, which is an olanzapine compound, was protected by the
10. See, e.g., James H. Madison, Manfacturing Pharmaceuticals: Eli Lilly and Company, 1876-1948, 18 Bus.
& EcON. HISTORY 72, 72 (1989), available at http://www.thebhc.org/publications/BEHprint/v018/p0072-
p0078.pdf.
11. See Sensory Technologies Designs &r Integrates Immersive Collaborative Erperiences for Eli Lilly, PROF. Sys.
NETwoRx INT'L, http://www.psni.org/project/sensory-technologies-designs-integrates-immersive-collabo-
rative-experiences-for-eli-lilly/ (last visited Feb. 5, 2014).
12. See, e.g., Thomas M. Burton, Eli Lilly Leveraging Prvzac Success into New Drug Developments, Scmzo-
PHRENIA.COM, http://www.schizophrenia.com/news/elilily.htmi (last visited Feb. 5, 2014) ("Eli Lilly & Co.
shot to the forefront of psychiatric therapy . . . .").
13. See, e.g., Bethany McLean, A Bitter Pill Prozac Made Eli Lilly. Then Along Came a Feisty Generic Maker
Called Barr Labs. Their Battle Gives New Meaning to the Term 'Drug War.', FORTUNE, Aug. 13, 2001, at 118,
available at http://money.cnn.com/magazines/fortune/fortune_archive/2001/08/13/308077/.
14. See, e.g., Key Facts, LILLY, http://www.lilly.com/about/key-facts/Pages/key-facts.aspx (last visited Feb. 5,
2014) (comparing the number of Lilly employees worldwide [38,000] to the number of Lilly employees exclu-
sively outside of the United States [21, 437]).
15. See generally id.
16. See, e.g., The Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417,
98 Stat. 1585 (1984) (codified at 21 U.S.C. §§ 355, 360cc; 35 U.S.C. §§ 156, 271), as amended by the Medi-
care Prescription Drug Improvement and Modernization Act of 2003, Pub. L. No. 108-173, 117 Stat. 2066
(2003) (also known as the Hatch-Waxman Act).
17. See, e.g., Drugs and Health Products, Drug Products, HEALTH CAN., http://www.hc-sc.gc.ca/dhp-mps/
prodpharma/index-eng.php (last visited Feb. 5, 2014) ("Before drug products are authorized for sale in Ca-
nada, Health Canada reviews them to assess their safety, efficacy and quality. Drug products include pre-
scription ... pharmaceuticals . . . .").
18. See Matthew Herper, The Cost of Creating A New Drug Now $5 Billion, Pushing Big Pharma to Change,
FORBES (Aug. 11, 2013, 11:10 AM), http://www.forbes.com/sites/matthewherper/2013/08/1 1/how-the-stag
gering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/.
19. Notice of Arbitration, supra note 1, 1 2.
20. Thomas Cheng, Putting Innovation Incentives Back in the Patent-Antitrust Interface, 11 Nw J. TECH. &
INTELL. PROP. 385, 387 (2013), available at http://scholarlycommons.law.northwestem.edu/cgi/viewcontent
.cgi?article= 1l95&context=njtip.
21. See Notice of Arbitration, supra note 1, 1 26-27.
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'113 patent, a secondary patent that issued in 1998.22 Regarding the '113 patent, Lilly
claimed that the disclosed compound had "surprising and excellent results,"23 "marked
superiority, and a better side effects profile than prior known antipsychotic agents." 24
Strattera, which is atomoxetine, was protected by the '735 patent.25 The '735 patent dis-
closed using atomoxetine for ADHD treatment, contrasted with its use as an anti-depres-
sant.26 Lilly demonstrated that "atomoxetine could be use[ful] in the treatment of
ADHD" with results from an internal 22-patient study.27
Roughly twenty years after grant of the Lilly patents, Zyprexa and Strattera are pre-
scribed to hundreds of thousands of Canadians and net billions of dollars in annual sales
worldwide.28 Zyprexa, referred to by Lilly as its "breakthrough product for schizophrenia
and bipolar mania," 29 landed its inventors the prestigious "PhRMA Discoverers Award" in
200030 and amounted to 22 percent of Lilly's revenues in 2010.31 In a similar fashion,
Strattera has made waves as "the first nonstimulant, noncontrolled drug approved for at-
tention-deficit hyperactivity disorder" in all age groups. 32 Still, the Court of Appeal ulti-
mately invalidated the Lilly patents after finding that their respective medicines lacked
utility under the Canada Patent Act (the Patent Act).33
A. THE PATENT ACT'S UTruTy REQUIREMENTS AND THE PROMISE DocTRINE
The Patent Act empowers the owner of a patent for an invention with "the exclusive
right, privilege and liberty of making, constructing and using the invention and selling it
to others to be used." 34 Similarly to other national patent systems, the Patent Act estab-
lishes a framework that limits patent grants to useful, novel, and non-obvious inventions,
exclusively. 35 Specifically, Section 2 of the Patent Act defines "invention" as "any new and
useful art, process, machine, manufacture or composition of matter, or any new and useful im-
22. See CA Patent No. 2,041,113 (filed Apr. 24, 1991).
23. Id. at 4.
24. Id. at 6.
25. See CA Patent No. 2,209,735 (filed Apr. 24, 1991).
26. See id.
27. Notice of Arbitration, supra note 1, 49-50.
28. See id. 26 - 27.
29. Lilly Announces Fourth-Quarter Earnings Per Share of $. 60, Excluding One-Time Charges, LILLY, https://
investor.lilly.com/releasedetail2.cfn?releaseid=70219 (last visited Feb. 5, 2014).
30. See, e.g., Discoverers Awards, INNoVATION, http://www.innovation.org/index.cfm/StoriesofInnovation/
InnovatorStories/DiscoverersAwards (last visited Feb. 5, 2014).
31. See, e.g., Tom Randall & Elizabeth Lopatto, Lilly Reports Profit Higher Than Analysts Ertimated, Misses on
Forecast, BLOOMBERG (an. 27, 2011, 8:54 AM), http://www.bloomberg.com/news/2011-01-27/lilly-fourth-
quarter-profit-increases-more-than-analysts-estimated.html.
32. RUH WOODROw, BRUCE COLBElr & DAviD M. SMITH, EssErcnALs OF PHARMACOLOGY FOR
HEALTH OCCUPATIONs 352 (6th ed. 2011) (emphasis omitted).
33. See Eli Lilly Can. Inc. v. Novopharm Ltd., [20121 F.C.A. 232 (Can.); see also Eli Lilly & Co. v. Teva
Can. Ltd., 2011] F.C.A. 220 (Can.).
34. Canada Patent Act, R.S.C. 1985, c. P-4, § 42, available at http://laws-lois.justice.g.ca/PDF/P-4.pdf
[hereinafter Patent Act].
35. See id. § 28.3.
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provement [thereofl."36 Hence, utility is indispensable for obtaining and maintaining a pat-
ent in Canada.37
The current requirements for utility, largely promulgated by the Supreme Court of
Canada (the Supreme Court), set out that an invention possesses utility only if "when used
in accordance with the directions contained in the specification the promised results are
obtained." 38 Whether promised results are obtained is a question of fact and must be
shown by "either demonstration or sound prediction based on the information and expertise
then available."39 Moreover, a sound prediction exists only when there is (1) "a factual
basis for the prediction"; (2) "an articulable and 'sound' line of reasoning from which the
desired result can be inferred from the factual basis" upon filing; and (3) "proper disclo-
sure."40 These judge-propounded conditions for invention utility comprise the promise
doctrine. 41
Pharmaceutical companies have a particularly difficult time satisfying the promise doc-
trine's requirements because of the Phase II human testing that medicines must undergo
for federal approval. 42 Some argue that requiring the promise doctrine to be met for
utility, in addition to fulfilling the statutory patent novelty, creates a "catch-22." 43 Specif-
ically, to soundly predict that a medicine's promises are sufficiently accurate, it must be
subject to Phase II trials, which require public disclosure that will likely result in a statu-
tory bar against novelty.44 Ironically, the promise doctrine originated "to allow inventors
to expand claims to cover a class of compounds or processes that had not all been
tested."45 Since its gestation, however, it has evolved into a pharmaceutical patent invali-
dation tool in Canada-and the basis for Lilly's NAFTA dispute against Canadian
sovereignty.46
B. LIlGATION OF THE '113 PATENT
Lilly sued Novopharm Limited (Novopharm) for patent infringement of the '113 pat-
ent, which in turn contested the '113 patent's validity.47 On October 5, 2009, the Canada
Federal Court (the Trial Court) nonsuited Lilly's patent infringement claims against
36. Id. § 2 (emphasis added).
37. See generally id.
38. Consolboard, Inc. v. MacMillan Bloedel (Sask.), Ltd., [1981) 1 S.C.R. 504, 526 (Can.) (emphasis
added).
39. Apotex, Inc. v. Wellcome Found. Ltd., [20021 4 S.C.R. 153, 155 (Can.) (emphasis added).
40. Id.
41. See id.
42. See, e.g., John Lechleiter, How Lax Patent Rules In Canada Are Suffocating Life-Saving Innovation, FORBES
(Aug. 26, 2013, 9:00 AM), http://www.forbes.com/sites/johnlechleiter/2013/08/26/how-lax-patent-rules-in-
canada-are-suffocating-life-saving-innovation/.
43. See, e.g., id.
44. See, e.g., Douglas K. Norman, Opportunities and Challenges in the Search for New Medicines,
PHARMAPHORUM (Sept. 25, 2013), http://www.pharmaphorumn.com/articles/opportunities-and-challenges-
in-the-search-for-new-medicines.
45. Brian R. Daley, Does the Doctrine of Sound Prediction Make it Harder for Inventive People to Obtain Patents
in Canada?, 27 CAN. INTELL. PROP. REv. 363, 363 (Dec. 2011), available at http://www.nortonrosefulbright
.com/files/does-the-doctrine-of-sound-prediction-make-it-harder-for-inventive-people-to-obtain-patents-in-
canada-pdf-220kb-64162.pdf.
46. See generally Notice of Arbitration, supra note 1.
47. Eli Lilly Can. Inc. v. Novopharm Ltd., [20091 F.C. 1018, 1 1 (Can.).
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Novopharm in finding that the '113 patent was invalid as a selection patent.48 The Court
of Appeal reversed this decision on July 21, 2010, in part because "the conditions for a
valid selection patent [do not] constitute an independent basis upon which to attack the
validity of a patent." 49 The Court of Appeal held that the '113 patent was both novel and
non-obvious and remanded for addressing whether it possessed utility.50
The Trial Court revisited the case and on November 10, 2011, it nonsuited Lilly's
claims once more.5 This time it found that the '113 patent lacked utility in failing to
meet its promise of "marked superiority" over related compounds. 52 Specifically, the Trial
Court Justice explained that,
If the utility of the invention in the '113 [sic] patent relates merely to a compound
with potential antipsychotic properties that might have relatively low [side effects],
that utility had been demonstrated by the tests conducted prior to the filing date.
However, I cannot accept that the ' 13's [sic] promise was so small . .. . [B]ased on
the wording of the '113 [sic] patent . . . I find that the promise of the patent is that
olanzapine treats schizophrenia patients in the clinic in a markedly superior fashion
with a better side-effects profile than other known antipsychotics . . . . [W]here a
patented compound is claimed to be safe and effective in the treatment of a chronic
condition, utility will be demonstrated if the patent discloses studies showing that the
patented compound, when administered over a long term, meets that promise . . . .s3
Again, Lilly appealed the findings to the Court of Appeal.5 4 In a decision on September
10, 2012, the Court of Appeal affirmed the Trial Court on the same grounds.55 In re-
sponse, Lilly applied for leave to appeal to the Supreme Court, but the application was
denied.56
C. LrIGATION OF THE '735 PATENT
Novopharm brought a patent impeachment action to contest the '735 patent's validity,
in part based upon utility.5 7 On September 14, 2010, the Trial Court invalidated the '735
patent in finding it lacked utility under the promise doctrine.58 Specifically, the Trial
Court explained that,
In this case the requirement of utility would be met if, at the Canadian filing date of
the '735 [p]atent, there was sufficient evidence that atomoxetine was clinically useful
in treating some patients with ADHD or, alternatively, that such efficacy could be
soundly predicted . . . . [T]he inventors claimed a new use for atomoxetine to effec-
48. See id.
49. See Eli Lilly Canada Inc. v. Novopharm Ltd., [20101 FCA. 197 (Can.).
50. Id. 1 124.
51. See Eli Lilly Canada Inc. v. Novopharm Ltd., [20111 F.C. 1288 (Can.).
52. Id. 1 262.
53. Id. 19 209-10 (emphasis added).
54. See generally Eli Lilly Can. Inc. v. Novopharm Ltd., [20121 F.C.A. 232 (Can.).
55. Id. 11 1-2.
56. See Eli Lilly Can. Inc. v. Novopharm Ltd., [2013] CanLII 26762 (Can.).
57. Novopharm Ltd. v. Eli Lilly & Co., [2010] F.C. 915, 9| 1 (Can.).
58. Id. 1 122.
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tively treat humans with ADHD. What is implicit in this promise is that atomoxetine
will work in the longer term.59
Lilly appealed the findings to the Court of Appeal.60 On July 5, 2011, the Court of
Appeal affirmed the Trial Court.61 Although Lilly responded by applying for leave to
appeal to the Supreme Court, the application was denied.62
D. PosT-INVALIDATION
On November 7, 2012, Lilly filed a notice of intent to arbitrate under NAFTA Chapter
11 against Canada, claiming CND $100 million in damages. 63 The notice focused on the
Court of Appeal's invalidation of the '735 patent, which allowed for Strattera generics.-
Thereafter, Lilly engaged in pre-arbitration negotiations with Canada as mandated by
NAFTA.65 But on June 13, 2013, after concluding that negotiations lacked resolve, Lilly
filed a second notice of intent to arbitrate against Canada.66 The second notice ratcheted
up the damages being sought to CND $500 million, to account for lost Zyprex sales since
the '113 patent's invalidation. 67
Then, on September 12, 2013, Lilly filed its precedential arbitration notice against Ca-
nada under Chapter 11 for breach of Articles 1110 and 1105, for domestic court applica-
tion of the promise doctrine.68 In addition to being the first attempt to contest a Party's
patent regime, this case is notable because Lilly is disputing the application of the promise
doctrine as applied to the Lilly patents-not the promise doctrine itself.69 Lilly supported
its claims, in part, with Canada violations under NAFTA Chapter 17 and the Patent Co-
operation Treaty (PCT).70
M. The Viability of Lilly's NAFTA Chapter 11 Claims
A. A BRIEF SYNoPsIs OF NAFTA
The provisions in NAFTA have been legally binding on Canada, the United States, and
Mexico since 1994.71 A bilateral investment treaty, NAFTA was enacted to "create an
expanded and secure market for the goods and services produced in their territories." 72
59. Id. TT 93, 112 (emphasis added).
60. See generally Eli Lilly & Co. v. Teva Can. Ltd., [2011] F.C.A. 220 (Can.).
61. Id. T 7.
62. See Eli Lilly & Co. v. Teva Can. Ltd., [2011] CanLI 79177 (Can.).
63. Notice of Intent to Submit a Claim to Arbitration Under NAFTA Chapter Eleven, Eli Lilly & Co. v.
Can., T 108 (Nov. 7, 2013), available at http://italaw.com/sites/default/files/case-documents/italawl172.pdf.
64. See generally id.
65. See Notice of Arbitration, supra note 1, T 19.
66. See Notice of Intent to Submit a Claim to Arbitration Under NAFTA Chapter Eleven, Eli Lilly & Co.
v. Can. (June 13, 2013), available at http://italaw.com/sites/default/files/case-documents/italawl530.pdf
67. See id. T 119.
68. See generally Notice of Arbitration, supra note 1.
69. See Jishnu, supra note 2.
70. See Notice of Arbitration, supra note 1, 'IT 75, 84.
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Specifically, NAFTA attempts to break down international trade barriers in order to pro-
mote existence of beneficial investment opportunities amongst Parties.73 Also, NAFTA
provides for increased intellectual property rights protections and enhanced enforcement
mechanisms beyond those available on the national level. 74 Each Party is required to
"ensure that all necessary measures are taken" to uphold NAFTA's provisions at all levels
of Party government. 75
Chapter 11, dubbed the "investor-state provision,"76 provides direct redress against a
Party whose "measures adopted or maintained" result in an investor from another Party
being treated inequitably. 77 For investor protection, Article 1110 prohibits Parties from
"directly or indirectly nationaliz[ing] or expropriat[ing] an investment of an investor of
another Party in its territory or take a measure tantamount to" such.78 An exception to
this exists when such nationalization or expropriation is (A) "for a public purpose"; (B) "on
a non-discriminatory basis"; (C) "in accordance with due process of law and Article
1105(1)"; and (D) compensated for.79 Article 1105 establishes minimum standards of
treatment for investors within the Parties.80 Article 1105(1) requires each Party to treat
any investments of the other Parties' investors "in accordance with international law, in-
cluding fair and equitable treatment and full protection and security."8'
Chapter 17 sets out intellectual property rights protections, including patent rights. 82
Article 1701(1) mandates each Party to provide the other Parties' investors "adequate and
effective protection and enforcement of intellectual property rights, while ensuring that
measures to enforce intellectual property rights do not themselves become barriers of
legitimate trade."83 Article 1709, concerning patent rights exclusively, mandates in part
that Parties "make patents available for inventions ... provided that such inventions are
new, result from an inventive step, and are capable of industrial application."8 4 Further,
these "patents shall be available and patent rights enjoyable without discrimination."ss
But an exclusion from patentability applies in part "if preventing in its territory the com-
mercial exploitation . . . is necessary to protect [public policy] . . . including to protect
human . . . life or heath" 86 or "diagnostic, therapeutic and surgical methods for the treat-
73. See id. ("[Each Party] resolved to: . . . CONTRIBUTE to the harmonious development and expansion
of world trade and provide a catalyst to broader international cooperation; ... REDUCE distortions to trade;
. . . [and] ENSURE a predictable commercial framework for business planning and investment . . . .").
74. See id. ("[Each Party] resolved to: ... FOSTER creativity and innovation, and promote trade in goods
that are the subject of intellectual property rights . . . ."); see also id. art. 102(l)(d) (stating that one objective of
NAFTA is to "provide adequate and effective protection and enforcement of intellectual property rights in
each Party's territory").
75. See id. art. 105.
76. Andrew J. Shapren, NAFTA Chapter Il:A Step Forward in International Trade Law ora Step Backward for
Democracy?, 17 TEMp. INT'L & COMP. LJ. 323, 326 (2003) ("Chapter 11 of NAFTA, the investor-state
provision, sets forth the rules governing the treatment and protection of foreign investments . . .
77. NAFTA, supra note 71, art. 1101(1).
78. Id. art. 1110(1).
79. Id. art. 11 10(1)(a)-(d).
80. See generally id. art. 1105.
81. See id. art. 1105(1).
82. See generally id., ch. 17.
83. Id. art. 1701(1).
84. Id. art. 1709(1).
85. Id. art. 1709(7).
86. Id. art. 1709(2).
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ment of humans." 87 Even though the exclusions concern pending patents, Article 1709(8)
allows for patent revocation if "grounds exist that would have justified a refusal to grant
the patent."88
Although NAFTA's principle purpose is to promote and effectuate international com-
merce, it also applies to social services. 89 NAFTA partially does this by preserving the
Parties' "flexibility to safeguard the public welfare."90 But all investment treaties attempt
to "internationalize[] the scope of the value judgments made by domestic judges," which
inherently limits domestic judge decision-making discretion.91 NAFTA critics urge, how-
ever, that these effects extend even broader-"chill[ing] . . . [legislative] regulation that
happens to interfere with investment." 92 In sum, vetting NAFTA's positive impact on
business against its positive impact on public interest will reveal "that [NAFFA] favors
investor rights over public welfare."93
B. ANALYsIs
Both of Lilly's claims will likely succeed in arbitration. NAFTA Article 1139 defines
"investment" to include all "property, tangible or intangible, acquired in the expectation
or used for the purpose of economic benefit."9 4 Because "[p]harmaceutical inventions
typically involve investment of capital or other resources during the research and develop-
ment process,"95 the Lilly patents qualify as "investments" under Chapter 11. With this,
Lilly comports as an "investor of a[nother] Party" under the same because it is "an enter-
prise of [the United States], that . . . has made an investment" in Canada.96
Lilly's first claim is expropriation under Article 1110.97 Although Article 1110 does not
specify what measures constitute direct (or indirect) expropriation, 98 scholars have stated
87. Id. art. 1709(3)(a).
88. Id. art. 1709(8)(a).
89. See, e.g., Eleanor D. Kinney, Realizing the International Human Right to Health for Non-Citizens in the
United States, NOTRE DAME J. INT'L COMP. & Hum. RTs. L. 94, 108 (2011), available at http://www3.nd
.edu/-ndjicl/Vlll/Kinney%20Article.pdf ("NAFTA applies to all economic sectors including social
services.").
90. NAFTA, supra note 71, pmbl.
91. AndrewJ. Walker, Conflict ofLaws Analyses for the Era ofFree Trade, 20 AM. U. INT'L L. REv. 1147, 1148
(2005), available at http://digitalcommons.wcl.american.edu/cgilviewcontent.cgi?article= 1155&context=auilr.
92. John B. Fowles, Swords into Plowshares: Softening the Edge of NAFTA's Chapter 11 Regulatory EApropria-
tions Provisions, 36 CUMB. L. Riv. 83, 84 (2006).
93. Id.
94. NAFTA, supra note 71, art. 1139.
95. Brook K. Baker, Corporate Power Unbound: Investor-State Arbitration of IP Monopolies on Medicines-Eli
Lilly and the TPP, PROGRAM ON INFO. JUST. & INTELL. PROP. R-ESEARCH PAPER SERIES 1, 13 (2013), availa-
ble at http://digitalcommons.wcl.american.edu/cgi/viewcontent.cgi?article=1038&context=research.
96. Id. at 12; see also NAFTA, supra note 71 art. 1110 ("No Party may directly or indirectly ... expropriate
an investment of an investor of another Party ... .") (emphasis added).
97. See Notice of Arbitration, supra note 1, 11 74-79.
98. See, e.g., Brynn Olsen, International Local Government Law: The Effect ofNAFTA Chapter 11 on Local Land
Use Planning, 4 BYU INT'L L. & MGMT. REv. 53, 57 (2007), available at http://www.law2.byu.edu/ilmr/
articles/winter._2007/BYU_1LMR winter_2007_3_Olsen.pdf ("NAFTA does not explicitly define either 'ex-
propriation' or 'a measure tantamount to ... expropriation.'").
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that at least "openly avowed state takings of property" will qualify.99 Lilly's case satisfies
this standard. Lilly had the patents and enjoyed their privileges for many years before
Canada stripped them of their legal and monetary value.'1 At the very least, Lilly's cir-
cumstances amount to "a measure tantamount to ... expropriation."' 0' Article 201 de-
fines "measure" to include "any law, regulation, procedure, requirement, or practice."l 02
This is sufficiently broad to encompass the promise doctrine, which literally is a "require-
ment" for patent utility. 0 3 In determining if a requirement netted an equivalent result to
expropriation, tribunals frequently inquire into whether Party action substantially de-
prived a foreign investor of its investment,'04 as is the case here with invalidation of the
Lilly patents.
Lilly also raises a minimum standard of treatment claim under Article 1105.105 Article
1105 does not specify what rises to the "fair and equitable treatment" that Parties must
accord to foreign investors. 0 6 Accordingly, tribunals vary in how fair and equitable treat-
ment should be applied and under which international body of law.' 07 Still, the facts are
uncontroverted, and discrimination is clear; the effect of the promise doctrine's applica-
tion nets in invalidation of pharmaceutical patents exclusively and without legal cause. 00
Moreover, its application results in "manifest arbitrariness [and] blatant unfairness,"109 at
least because of the paradoxical effect stemming from patent novelty requirements and
mandatory Phase H testing.
Jurisprudence analysis is one method of defining how a tribunal will decide. 0 But the
jurisprudence is inconsistent because of the non-binding treatment it is accorded for sub-
sequent determinations." I Still, prior jurisprudence holds some degree of credibility and
99. WILLIAM W. PARK, ARBITRATION OF INTERNATIONAL BUSINESS DISPUTES: STUDIES IN LAW AND
PRACTICE 710 (2d ed. 2012), available at http://www.law.yale.edu/documents/pdf/sela/ChapterIV-D-2_In
vestment_Arbitration.pdf.
100. See generally Notice of Arbitration, supra note 1.
101. NAFTA,supra note 71, art. 1110(1).
102. Id. art. 201 (emphasis added).
103. See Apotex, Inc. v. Wellcome Found. Ltd., [2002] 4 S.C.R. 153, 155 (Can.).
104. KHAWAR QURESHI QC, McNAIR CHAMBERs, BILATERAL INVESTMEN-T TREATIES (BITS): THE Es-
SENTIALs 1, 8 (Oct. 2008), available at http://www.mcnairchambers.com/media/documents/200810/Invest
mentTreatyEssentials..pdf ("Key Test: Whether action of a state deprives investor of the whole or significant
part of investment") (emphasis omitted).
105. See Notice of Arbitration, supra note 1, 1J 80-84.
106. Kara Dougherty, Methanex v. United States: The Realignment of NAFTA Chapter 11 with Environmental
Regulation, 27 NwJ. LNT'L L. & Bus. 735, 744 (2007), available at http://scholarlycommons.law.northwestem
.edu/cgi/viewcontent.cgi?article=1661 &context=njilb.
107. See, e.g., Adnan Kagalwalla, NAFTA Chapter 11 Tribunals and Their Impact on Signatory States: A Parallel
Judicial System and Its Many Potential Dangers, 3 ENTREPRENEURIAL Bus. L. J. 95, 109 (2008), available at
http://moritzlaw.osu.edu/students/groups/oseblj/files/2013/04/3-6.pdf ("[Bjecause of the lack of precedent in
the NAFTA Chapter 11 tribunal system, the decisions [will] appear at odds with each other.").
108. In Azinian v. United Mexican States, the tribunal found that "the Claimants must show either a denial
of justice, or a pretence of form to achieve an internationally unlawful end." As will be shown, it is a posture
of this note that the promise doctrine will satisfy either of these requirements. Azinian v. United Mexican
States, ICSID Case No. ARB(AF)/97/2, Award (Nov. 1, 1999), 14 ICSID Rev.-Foreign Inv. LJ. 68 (1999).
109. Glamis Gold, Ltd. v. United States, Award % 22, NAFTA Ch. 11 Arb. Trib. fune 8, 2009).
110. See Kagalwalla, supra note 107, at 111.
Ill. See id. at 109.
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influence with other tribunals and, thus, can be useful in determining legal boundaries."12
This note will analyze Lilly's claims against two determinations where the claimant's Arti-
cle 1110 and 1105 claims each failed, Azinian v. United Mexican States'"3 and Glamis Gold
Ltd. v. United States. 114
In Azinian, a Mexican waste collection company filed claims, under Article 1110 and
1105, against Mexico for allowing its domestic courts to annul its work contract with a
Mexican city on grounds that it was void or rescindable for non-performance."15 In find-
ing that the core of the claimant's Article 1110 claim was for "breach of [a] Concession
Contract," the tribunal concluded that mere contractual breach is insufficient under
NAFTA.116 The tribunal did note that "[t]he words 'confiscatory,' 'destroy contractual
rights as an asset,' or 'repudiation' may serve . . . as acts of expropriation."" 7 Further, it
determined that a Party cannot be liable "for acting in a manner validated by its courts
unless the courts themselves are disavowed at the international evel . . .. [T]he Claimants must
show either a denial of justice, or a pretence of form to achieve an internationally unlawful
end."Is In rejecting the Article 1105 claim, the tribunal determined that "[t]he only con-
ceivably relevant substantive principle of Article 1105 is that a NAFTA investor should
not be dealt with in a manner that contravenes international law.""l9
In Glamis Gold, a Canadian mining company filed claims, under Article 1110 and 1105,
against the United States for allowing a California law that mandated backfilling of open-
pit mining operations near Native American sacred sights.120 For the Article 1110 claim,
the tribunal determined that the claimant must be "radically deprived of the economical
use and enjoyment of its investments, as if the rights related thereto . . . had ceased to
exist."'21 On this, it concluded that the mandatory backfilling did not constitute an Arti-
cle 1110 violation primarily because the "claimant still formally possessed its mining rights
and could exploit mineral resources at a profit," only under modified circumstances.122
Regarding the claimant's Article 1105 claim, the tribunal decided that Article 1105 should
be decided under customary international law.
[A] violation of the customary international law minimum standard of treatment ...
requires an act that is sufficiently egregious and shocking-a gross denial of justice,
manifest arbitrariness, blatant unfairness, a complete lack of due process, evident dis-
112. See, e.g., Alberto R. Salazar V., NAFTA Chapter 11, Regulatory Erpropriation, and Domestic Counter-Ad-
vertising Law, 27 ARz. J. INr'L & COMP. L. 31, 50 (2010), available at http://www.ajicl.org/AJICL2010/
2.27.lSalazar.pdf ("Although the [] decisions do not set binding precedents and the principles of stare decisis
do not apply, decisions . . . may become influential in narrowing the definition of expropriation and setting
out the scope of a government's regulatory power under NAFTA").
113. See generally Azinian, ICSID Case No. ARB(AF)/97/2, Award.
114. See generally Glamis Gold, Award T 10.
115. See Azinian v. United Mexican States, ICSID Case No. ARB(AF)/97/2, Award (Nov. 1, 1999), 14 IC-
SID Rev.-Foreign Inv. LJ. 68, T 35 (1999).
116. Id. 87.
117. Id. 9190.
118. Id. 9 99 (emphasis added).
119. Id. 92.
120. See generally Glamis Gold, Ltd. v. United States, Award T 10, NAFTA Ch. 11 Arb. Trib. (June 8,2009).
121. Id. 357.
122. See Stephen W. Schill, Glamis Gold, Ltd. v. United States, 104 Am. J. Irr'L L. 253, 255 (2010) (citing
Glamis Gold, Award 1 353 - 536).
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crimination, or a manifest lack of reasons-so as to fall below accepted international
standards . . . .123
The tribunal did not find that the California law specifically targeted the claimant's
investment but instead that it was general applied in both form and effect.124 More, the
California law was found to be rationally related to legitimate government interests, thus
not manifestly arbitrary.125
Lilly's case diverges from both Azinian and Glamis Gold on its merits. Lilly's Article
1110 claim is distinct from that in Azinian because domestic Canadian courts applied the
promise doctrine in a way that amounted to "a denial of justice," 26 and is "disavowed at
the international level."' 27 Indeed, the promise doctrine only exists in Canada,128 and
only three other countries have an arguably similar restriction.129 Further, Lilly's Article
1110 claim is dissimilar from that in Glamis Gold because Lilly lost significant monetary
and legal privileges when the Lilly patents were invalidated. 30 Today, the Lilly patents
have zero significance because they neither protect Lilly's rights to the respective technol-
ogies, nor can they be exploited for profit; they have effectively "ceased to exist."' 3'
For Article 1105 purposes, both Azinian and Glamis Gold diverge from Lilly's claim on
their merits. Under Azinian, Lilly's claim stands; the Canadian courts' application of the
promise doctrine "contravenes international law."' 32 The promise doctrine has only been
used to expropriate from the pharmaceutical industry and has only been applied in Ca-
nada. 33 More, Lilly's Article 1105 claim holds merit under Glamis Gold. The promise
doctrine's application leads to "manifest arbitrariness, blatant unfairness . . . [and] evident
discrimination" in form and effect.134 Zyprexa and Strattera have achieved vast notoriety
in Canada, 35 but that is a nonfactor to patent utility; promises must be proven as of the
filing date.136 This is manifestly arbitrary and blatantly unfair because it "establishes an
impractical evidentiary burden since it is impossible to predict at the date of filing how
123. Glamis Gold, Award 1 627.
124. See Schill, supra note 122, at 257.
125. See id.
126. Azinian v. United Mexican States, ICSID Case No. ARB(AF)/97/2, Award (Nov. 1, 1999), 14 ICSID
Rev.-Foreign Inv. LJ. 68, 1 100 (1999).
127. Id. 97.
128. See Livia Aumand, Court of Appeal Tempers "Promise of the Patent" Doctrine, GOWLINGS (uly 2013),
http://www.gowlings.com/KnowledgeCentre/article.asp?publD=2966 ("The doctrine of the 'promise of the
patent' is unique to Canadian patent law.").
129. See Rajarshi Banerjee, The Success of and Response to, India's Law against Patent Layering, 54 HARVARD
INT'L LJ. 204, 206 (2013), available at http://www.harvardilj.org/wp-content/uploads/2013/06/Banerjee-to-
Publish.pdf ("[Dleveloping countries that wish to curb patent layering are taking note of India's law, and at
least two countries-the Philippines and Argentina-have adopted similar provisions."). R. Banerjee's note
discusses § 3(d) of the India Patents (Amendment) Act, an anti-"patent evergreening" measure that adds an
additional requirement to patent novelty. See generally id.
130. See Schill, supra note 122, at 255.
131. Glamis Gold, Ltd. v. United States, Award 1 357, NAFTA Ch. 11 Arb. Trib. (une 8, 2009).
132. Azinian v. United Mexican States, ICSID Case No. ARB(AF)/97/2, Award (Nov. 1, 1999), 14 ICSID
Rev.-Foreign Inv. Lj. 68, 1 92 (1999).
133. See Aumand, supra note 128.
134. Glamis Gold, Award 627.
135. See Notice of Arbitration, supra note 1, 26-27.
136. See id., 1 35.
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specifically useful a patent is."I37 It could be argued that the promise doctrine does not
discriminate because the "promise" disclosure within the patent is not legally required of
by the patentee and it does not exclusively apply to pharmaceutical patents.138 But
"[u]nder Article 1101, the government 'measure' at issue must relate to an appropriate
investor or investment" and "tribunals (correctly) focus[] on the effects of the measure on
the business of the investor or investment." 39 Here, "the effects of the measure" clearly
discriminate against pharmaceutical industry investors. 40
It is worth noting that Articles 1709(2) and (3) should not bar Lilly's claims. Article
1709(2) allows exclusions to "protect human ... life or heath";141 thus, Canada would have
to concede that the promise doctrine intends to discriminate against pharmaceutical pat-
ents. But Lilly is contesting the promise doctrine's application under Canada's current
regulatory pharmaceutical frameworkl42-utility and novelty are at paradox with the
promise doctrine and Phase II testing requirements,143 rendering it out of sync with inter-
national law-and thus will still fail under international law. More, Article 1709(3) only
applies to the '735 patent (as "therapeutic . . . method[ I for the treatment of [ADHD in]
humans") 14 because the '113 patent does not disclose methods for treatment.145 Accord-
ingly, this provision at most should only affect claims related to the '735 patent.
IV. The Far-Reaching Consequences of Lilly's Dispute
NAFTA arbitration determinations only bind the respective parties and only apply to
the respective dispute.146 But even if Lilly's action is dismissed, NAFTA member states
(and frankly, member states to any free trade agreement) will likely feel an aftermath of
effects for some time. These effects could likely be attributable to major pharmaceutical
companies reallocating resources outside of, and reducing expenditures within, Canada,
and increased arbitration filings in response to patent invalidation by Canadian courts.
Now without question, the pharmaceutical industry is aware of the potential post-patent
invalidation redress mechanism that has existed beneath them for over two decades.147
Now that Chapter 11 has gained notoriety for this purpose, investment treaty Parties are
vulnerable "to a slew of investor-state attacks from other drug companies that have had
137. Michelle Wein, Is it Useful? A Drug Patent Enigma, THE INNOVATION FILES (Oct. 21, 2013), http://
www.innovationfiles.org/is-it-useful-a-drug-patent-enigma/.
138. See Aumand, supra note 128 ("Mhe promise doctrine holds that ifa patent promises a particular utility,
the patentee will have had to demonstrate or soundly predict that utility by the Canadian filing date.") (en-
phasis added).
139. Todd Weiler, NAFTA Chapter 11 Juriprudence: Coming Along Nicely, 9 Sw. J.L. & TRADE AMERICAS
245, 253 (2003), available at http://apps.americanbar.org/intlaw/hubs/programs/Annua0312.01.pdf.
140. Id.
141. NAFTA, supra note 71, art. 1709(2).
142. See Jishnu, supra note 2.
143. See Lechleiter, supra note 42.
144. NAFTA, supra note 71, art. 1709(3).
145. See CA Patent No. 2,041,113 (filed Apr. 24, 1991).
146. See Salazar, supra note 112.
147. See generally Notice of Arbitration, supra note 1.
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patents invalidated."148 A favorable determination for Lilly could have even worse conse-
quences. A windfall for Lilly may push the pharmaceutical industry into "unleash[ing] a
wave of challenges to patent decision in other countries which have bilateral investment
treaties with the United States or European Union." 49
Another potential consequence that is considerably more significant is the effect of
Lilly's complaint on future international negotiations. Lilly's dispute filing comes at a
time when investment treaties are widespread, abundant in quantity, and emerging into
existence at roughly one per annum. 50 Indeed, country leaders engaged in treaty negotia-
tions have taken stock of Canada's promise doctrine, as evidenced by emerging treaty
provisions.' 5 Two such treaties, the Trans-Pacific Partnership (TPP) and the Transatlan-
tic Trade and Investment Partnership/Transatlantic Free Trade Agreement (TTIP/
TAFTA), each propose to strengthen intellectual property rights.152 Although much of
what the TTIP/TAFTA entails remains confidential, a draft of the TPP was leaked and
provides a baseline for support. 5 3 Concerning patents exclusively, the TPP proposes to
loosen "standards of patentability, to eliminate certain patent exclusions, to extend patent
terms to compensate for regulatory delays, to limit required disclosures, to forbid pre-
grant opposition procedures, and to require data exclusivity and patent-registration
linkage"154-measures well beyond those in NAFTA.ss Only time will tell if the final
TPP will include a provision to purposefully render Party application of the promise doc-
trine treaty-incompliant.
V. Conclusion
Although Lilly's arbitration will not occur for several years, it is important to cogitate
on its implications today. Currently, the actual impact of Chapter 11 is unrefined; but this
is in a constant flux. Even though Lilly's arbitration is only binding on, and directly con-
148. US. Pharmaceutical Corporation Uses NAFTA Foreign Investor Privileges Regime to Attack Canada's
Medicine Patent Policy, Demand $100 Million for Denial ofa Patent, PUBLIC CrrzEN (Mar. 2013), https://www
.citizen.org/eli-lilly-investor-state-factsheet.
149. Stuart Trew, Eli Lilly's NAFTA Lawsuit Should Prompt Rethink ofInvestor 'Rights' Deals, RABBLE (Sept. 3,
2013), http://rabble.ca/blogs/bloggers/council-canadians/2013/09/eli-lillys-nafta-lawsuit-should-prompt-re-
think-investor-rig.
150. See Banerjee, supra note 129, at 228 ("Since TRIPS came into force in 1995, the United States and the
European Union . . . have signed about two dozen free trade agreements . . . .").
151. See id. at 231 (discussing that the leaked draft of the TPP includes a provision (Article 8.1) that ex-
pressly requires parties thereto to allow for patenting what Section 3(d) of the India Patents (Amendment)
Act disallows).
152. See, e.g., id.; see also Glyn Moody, EU Mandate for TAFTA Leaked: Includes Investor-State Dispute Resolu-
tion for Intellectual Monopolies, TECHDIRT (May 31, 2013, 12:13 AM) http://www.techdirt.com/articles/
20130530/12171523255/ (discussing that the European Parliament passed a resolution regarding TTIP/
TAFTA stating that it "should include strong protection of precisely and clearly defined areas of intellectual
property rights").
153. For the "Intellectual Property Rights Chapter" of the TPP, see generally Trans-Pacific Partnership,
Intellectual Property Rights Chapter, Sept. 2011, available at http://www.citizenstrade.org/ctc/wp-content/
uploads/201 1/10/TransPacificIPL.pdf.
154. See Baker, supra note 95, at 6 n.21.
155. For a comparison of the TPP and NAFTA, seeJLmMy H. Koo, TABLE COMPARING THE PATENT LAw
REGIMES: TPP vs. CANADA, MExuco, AND NAFTA, available at http://infojustice.org/wp-content/uploads/
2012/08/Koo-TPP-NAFTA-Canada-Mexico-version-08152012.pdf (last visited Feb. 5, 2014).
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cerns, Lilly and the Canadian sovereign, it is monumental in effect. Not only does this
scenario affect the everyday person and his or her ability to access critical medicines, but
also it affects global frameworks that may be coming sooner than later. Indeed, as evi-
denced by the draft TTP provisions and beyond,156 Lilly's dispute may have already left a
mark on the landscape of investment treaty negotiations that may indefinitely carry
forward.
156. See, e.g., Banerjee, supra note 129, at 231 (discussing that the leaked draft of the TPP includes a provi-
sion (Article 8.1) that expressly requires parties thereto to allow for patenting what Section 3(d) of the India
Patents (Amendment) Act disallows).
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